Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...4950515253545556575859...7475»
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Retrospective data, Journal:  Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. (Pubmed Central) -  Jun 6, 2019   
    In patients with type 3 neovascularization, almost all reactivation was noted within 15 months of the third anti-VEGF injection, suggesting the need for close follow-up and detailed examination during this period. Female patients with thick choroid should be monitored more frequently during this early period.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Elevated lipocalin-2 level in aqueous humor of patients with central retinal vein occlusion. (Pubmed Central) -  Jun 4, 2019   
    Concentrations of LCN2 in aqueous humor are increased in CRVO. LCN2 may be part of a pro-catabolic phenotype, and it may play an important role in the dreaded complications of CRVO, such as macular edema, macular ischemia, and neovascularization, which lead to blindness.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Observational data, Journal:  Intravitreal ranibizumab injection at the end of vitrectomy for diabetic vitreous hemorrhage (Observational Study). (Pubmed Central) -  May 30, 2019   
    Visual acuity 6 months after operation was better in IVR group (P<.01) There was no difference in mean intraocular pressure between the 2 groups (P=.56). The present clinical study suggests that intravitreal injection of ranibizumab is effective in the prevention of postoperative diabetic vitreous hemorrhage in eyes undergoing pars plana vitrectomy for the treatment of diabetic vitreous hemorrhage.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion. (Pubmed Central) -  May 30, 2019   
    Correlations among the aqueous flare value (an indicator of inflammation), functional-morphologic parameters, and aqueous humor levels of growth factors/receptors and inflammatory factors/cytokines were investigated in patients with central retinal vein occlusion (CRVO) and macular edema who received intravitreal ranibizumab injection (IRI) and were followed for 6 months...These findings suggest that IRI reduces inflammation and that the aqueous flare value is influenced by inflammatory factors/cytokines. In addition, the change of the aqueous flare value may be an indicator of the long-term prognosis in CRVO patients receiving IRI therapy for macular edema.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Xy31Prefilled syringes for intravitreal drug delivery. (Pubmed Central) -  May 23, 2019   
    This article discusses the advantages of the PFS, including reduced injection time, possible reduced risk of endophthalmitis, reduction in intraocular air bubbles and silicone oil droplets, and improved precision in the volume and dose of intravitreal ranibizumab administered, along with possible disadvantages. Implications of the innovation of the PFS on intravitreal injection technique and clinical practice pattern are discussed and reviewed.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Usability of the Ranibizumab 0.5-mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals. (Pubmed Central) -  May 18, 2019   
    P3
    Both the simulated-use and actual-use usability studies yielded consistent data, showing that healthcare professionals are able to use the ranibizumab PFS by successfully performing all critical tasks involved in preparing and delivering an intravitreal injection. The simulated-use usability testing was sufficiently realistic and representative of real world use, and was appropriate and preferred over actual-use usability testing for proper evaluation of the product user interface.
  • ||||||||||  NN1213 / Novo Nordisk, Lucentis (ranibizumab) / Roche, Novartis, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Enrollment closed, Trial completion date, Trial primary completion date:  TAPAS: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (clinicaltrials.gov) -  May 16, 2019   
    P2/3,  N=55, Active, not recruiting, 
    IVR combined with single or multiple spot PRP causes similar retinal function impairment during 48 weeks of observation, while IVR alone seems to be similarly effective controlling FLA without changing retinal function. Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> May 2020 | Trial primary completion date: Nov 2018 --> Nov 2019
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema. (Pubmed Central) -  May 8, 2019   
    Intravitreal ranibizumab injections did not seem to affect the refractive power of patients with diabetic macular oedema. Therefore, appropriate spectacle correction can be prescribed any time during ongoing treatment with ranibizumab injections.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  HORMONAL SUPPLEMENTATION TRIGGERING CHOROIDAL NEOVASCULARIZATION IN HEALTHY YOUNG FEMALES. (Pubmed Central) -  May 7, 2019   
    Hormonal supplementation for fertility therapy is a common procedure that may be associated with the development of choroidal neovascularization in healthy young females. Further studies should be performed to evaluate this association, but both ophthalmologist and gynecologist should be aware of this potential complication.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection. (Pubmed Central) -  May 7, 2019   
    Long-term suppression of neovascularization through SC administration of antiangiogenic drugs necessitates frequent injection or sustained delivery, such as microparticle-based delivery of antiangiogenic peptides. A comprehensive 3D model for intravitreal and SC drug injection is developed to provide a framework and platform for testing drug delivery routes and sustained delivery devices for new and existing drugs.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment open:  Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME (clinicaltrials.gov) -  May 7, 2019   
    P4,  N=72, Recruiting, 
    A comprehensive 3D model for intravitreal and SC drug injection is developed to provide a framework and platform for testing drug delivery routes and sustained delivery devices for new and existing drugs. Not yet recruiting --> Recruiting
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy (Pubmed Central) -  May 6, 2019   
    ...Twenty eyes of 14 patients (8 male, 6 female; mean age, 65±5.7 years) with DME resistant to intravitreal ranibizumab injections were studied...Intravitreal dexamethasone implant injection is associated with significant CFT reduction for up to six months without causing any complications. Although BCVA did not improve in parallel with the CFT reduction, intravitreal dexamethasone implant should be considered as an effective and safe treatment option in the management of DME patients resistant to anti-VEGF injections.
  • ||||||||||  Reimbursement, Journal, Medicare:  Medicare Spending on Anti-Vascular Endothelial Growth Factor Medications. (Pubmed Central) -  May 4, 2019   
    Ranibizumab and aflibercept costs account for 12% of the Medicare Part B budget annually. Bevacizumab represents a substantially more cost-effective alternative, but its use can present many obstacles, including efficacy concerns, dependence on compounding pharmacies, and off-label usage.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis. (Pubmed Central) -  May 4, 2019   
    The rates of cardiovascular and cerebrovascular events were low in these patients with nAMD and not clinically meaningfully different for patients treated with ranibizumab 0.5 mg versus sham or verteporfin, which supports the favorable benefit-risk profile of ranibizumab in the patient population with nAMD. Pooling these studies allows an analysis with higher power and precision compared with individual study analyses.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion:  Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema (clinicaltrials.gov) -  May 2, 2019   
    P=N/A,  N=51, Completed, 
    Finding anatomical predictors to identify this subgroup of patients would help to reduce treatment burden and optimize clinical outcomes. Active, not recruiting --> Completed
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Trial completion date:  ROTATED: IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab (clinicaltrials.gov) -  May 1, 2019   
    P4,  N=30, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jul 2019 --> Dec 2018